Inmedic Group ApS: Financial statements 2023
CVR: 40711171
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
Inmedic Group ApS (CVR 40711171) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK 562,047 and a net result of DKK 363,969 compared with DKK 433,331 the year before. That is an increase of 9.2% compared with the year before. Equity in the 2023 report amounted to DKK 1,125,686. The solvency ratio was 92%.
- Gross Profit
- DKK 562,047
- Profit/Loss
- DKK 363,969
- Equity
- DKK 1,125,686
- Total Assets
- DKK 1,223,223
- Employees
- 0
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | 562 t. | 364 t. | 1.1 mio. | 0 |
| 2022 | - | 514 t. | 433 t. | 762 t. | 0 |
| 2021 | - | -156 t. | -166 t. | 328 t. | 0 |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
Inmedic Group ApS has published its annual report for 2022. Gross profit came to DKK 514,472, and the net result was DKK 433,331.
About Inmedic Group ApS
Inmedic Group ApS is a Danish company of the type Anpartsselskab based in Vejle, founded in 2019. The company is registered under the industry Fremstilling af farmaceutiske råvarer. The company was previously named Nordic Cannabis Research ApS. The management consists of Henrik Lund Uth. The company is owned by DAM-ANDERSEN ApS, HEMAR ApS and Schejbel Holding ApS. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK 102,384 and a net result of DKK 563,568 compared with DKK 441,754 the year before. Equity in the 2025 report amounted to DKK 2,131,008.